Comparison of Devices for Atrial Septal Defects Closure: A Pilot Study

Atrial Septal Defect Clinical Trial

— Trio-ASD  

Official title:

Comparative Effectiveness of Three Devices for Transcatheter Closure of Atrial Septal Defects for Adults: A Pilot Study (Trio-ASD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04291898
• Other study ID #: 21-6095
• Secondary ID: TrioASD
• Status: Recruiting
• Phase: N/A
• Start date: November 23, 2022
• Est. completion date: October 1, 2024

Study information

• Verified date: April 2023
• Source: University Health Network, Toronto
• Contact: Lusine Abrahamyan, MD, PhD
• Phone: 416-340-4800
• Email: lusine.abrahamyan[@]theta.utoronto.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a proposal, for the first time in Canada, to examine the comparative effectiveness of three commercially available devices (ASO, FSO, and GAO/GSO) for transcatheter closure of atrial septal defects (ASD) in adults using a pilot randomized controlled trial.

Description:

The most widely used transcatheter device for ASD closure is the the Amplatzer Septal Occluder (ASO). Two other devices that entered the Canadian market are the Gore Cardioform ASD occluder (GAO) and the Figulla Flexible II Occlutech (FSO) device. There exists a paucity of data on the comparative efficacy and safety of these devices. This is a proposal, for the first time in Canada, to examine the comparative effectiveness of three commercially available ASD devices in an internal pilot randomized trial.

Approximately 60 patients referred for transcatheter ASD closure will be recruited in this study over a period of 15 months from 4 participating centers across Canada. This will be a registry-based randomized controlled trial (RRCT) where patients will be enrolled into one of three arms (ASO, FSO, and GAO/GSO) to compare the effectiveness and safety outcomes of three different ASD closure devices.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 110 Years

Eligibility

Inclusion Criteria:

• =18 years old referred for percutaneous (secundum) ASD closure with right atrial and ventricular enlargement; and

• clinically significant left-to-tight shunt (Qp:Qs=1.5:1), or

• evidence of paradoxical embolism (with a TEE defect >10mm),

• written informed consent

Exclusion Criteria:

• TEE/CCT/CMR defect diameter >30mm,

• rim sizes of < 5 mm to the coronary sinus, inferior vena cava rim, an atrioventricular valve, or the right upper pulmonary vein,

• multiple defects,

• complex congenital heart disease requiring surgical repair within 3 years of device placement,

• Eisenmenger-syndrome,

• recent myocardial infarction PCI/CABG < 6 weeks,

• demonstrated intra cardiac thrombi on echocardiography (especially LA or LAA thrombi), or atrial tumor

• known occluded bilateral femoral veins/IVC,

• pulmonary artery systolic pressure more than half the systemic systolic arterial pressure

• recent pelvic venous thrombosis

• serious comorbidity with life expectancy <3 years (e.g., non-skin cancers not in remission, advanced renal failure serum creatinine >160 umol/L)

• patients whose size or condition would cause the patient to be a poor candidate choice for cardiac catheterization (e.g., too small for echocardiographic imaging probe, catheter size, vascular size, active infection, body weight < 8 kg)

• serious infection in < 6 weeks producing bacteremia (e.g. sepsis), active endocarditis, or any other infection that cannot be treated successfully prior to device implantation (patient must have negative blood cultures off antibiotics for 1 week prior to procedure),

• active GI bleed < 6 weeks,

• bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy, unless another antiplatelet agent can be administered for 6 months

• previous stroke in the past 12 months,

• documented chronic atrial fibrillation or >2 episodes of documented paroxysmal atrial fibrillation in the last 12 months,

• pregnancy or breastfeeding, plan to become pregnant within the next 6 months, not using an effective method of birth control in premenopausal women,

• documented nickel/titanium allergy, or intolerance to contrast agents.

Related Conditions & MeSH terms

• Atrial Septal Defect
• Heart Septal Defects
• Heart Septal Defects, Atrial

Intervention

Device:
• AMPLATZER™ Septal Occluder.
Implantation of the AMPLATZER™ Septal Occluder in the ASD.
• Occlutech Figulla Flex II®
Implantation of the Occlutech Figulla Flex II® in the ASD.
• GORE® CARDIOFORM ASD Occluder
Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.

Locations

Country	Name	City	State
Canada	Institut de Cardiologie de Montreal (MHI)	Montréal	Quebec
Canada	Institut Universitaire de Cardiologie Et Pneumologie de Quebec/Hopital Laval	Québec	Quebec
Canada	Toronto General Hospital	Toronto	Ontario
Canada	St. Paul's Hospital	Vancouver	British Columbia

Sponsors (4)

Lead Sponsor	Collaborator
University Health Network, Toronto	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Montreal Heart Institute, St. Paul's Hospital, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite outcome of 'Clinical atrial fibrillation (AF)' or 'Major adverse cerebro-cardiovascular events (MACCE)	At 24 weeks where clinical (AF) includes AF-related, ECG-documented, ED visit/hospitalization/physician visit, cardioversion, ablation or pacemaker implantation or new antiarrhythmic or AF anticoagulant prescription'; MACCE includes 'new onset heart failure (HF), HF-related ED admission, myocardial infarction, stroke, re-intervention, or death.	24 weeks
Secondary	Subclinical AF (SCAF) burden (days):	Days with >6 min of AF detected on CardioSTAT monitor during 14 days	14 days
Secondary	Subclinical AF (SCAF) burden (number of episodes):	Number of episodes with >6 min of AF detected on CardioSTAT monitor during 14 days	14 days
Secondary	Subclinical AF (SCAF) burden (total time):	Total time in AF during 14 days	14 days
Secondary	Subclinical AF (SCAF) burden (percent time):	Percent time in AF during 14 days	14 days
Secondary	Procedural effectiveness outcomes (acute technical success rate at discharge)	Successful deployment and retention without major device related complications, stroke, myocardial infarction (MI) or arrhythmia requiring antiarrhythmic drug or cardioversion	Discharge, 24 weeks
Secondary	Procedural effectiveness outcomes (successful closure rate at discharge):	Negative bubble study or residual shunt <2mm	Discharge, 24 weeks
Secondary	Patient-reported outcomes (QoL):	Quality of life (QoL) using the EuroQoL (EQ-5D-5L™) at baseline, 6 weeks, 24 weeks	Baseline, 6 weeks, 24 weeks
Secondary	Patient-reported outcomes (healthcare utilization):	Healthcare utilization (ED admission, physician visit, etc) at 6 and 24 weeks	Baseline, 6 weeks, 24 weeks
Secondary	Patient-reported outcomes (SF-12):	Quality of life (QoL) using the SF-12 questionnaire at baseline, 6 weeks, 24 weeks	Baseline, 6 weeks, 24 weeks
Secondary	Patient-reported outcomes (HeartQOL):	Quality of life (QoL) using the HeartQOL questionnaire at baseline, 6 weeks, 24 weeks	Baseline, 6 weeks, 24 weeks
Secondary	Patient-reported outcomes (satisfaction with device):	Satisfaction with the use of CardioSTAT and KardiaMobile devices using a Likert scale at 24 weeks	24 weeks